Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genome-wide association study of high-sensitivity C-reactive protein, D-dimer and Interleukin-6 levels in multi-ethnic HIV+ cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Characteristics, interventions and longer-term outcomes of COVID-19 ICU patients in Denmark - a nationwide, observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.

Original languageEnglish
JournalThe Journal of infectious diseases
Volume222
Issue number7
Pages (from-to)1103-1107
Number of pages5
ISSN0022-1899
DOIs
Publication statusPublished - 1 Sep 2020

    Research areas

  • COVID-19, SARS-CoV-2, case report, immunocompromised, remdesivir, Severe Acute Respiratory Syndrome/drug therapy, Pandemics, Alanine/analogs & derivatives, Fever/drug therapy, Humans, Middle Aged, Leukemia, Lymphocytic, Chronic, B-Cell/complications, Male, Treatment Outcome, Adenosine Monophosphate/analogs & derivatives, Pneumonia, Viral/complications, Time Factors, Antiviral Agents/therapeutic use, Coronavirus Infections/complications, Immunocompromised Host, Betacoronavirus/drug effects

ID: 60480298